Our Founder and Director of Scientific Development, Mr. Steven Schutt, is pleased to acknowledge the discovery announced on January 16, 2011 by the Imperial College of London which substantiates his own research and analysis of protein behavior as outlined in his publication, “Free Amino Ion Theory.” [Full Imperial College of London Findings Here]
Dr. Irina Udalova, Senior Researcher at the Imperial College of London’s Kennedy Institute of Rheumatology, has identified a protein that acts as a “master switch” in certain white blood cells, determining whether the cells promote or inhibit inflammation of the protein identified as IRF5. Cells of the immune system called macrophages can either stimulate inflammation or suppress it by releasing chemical signals that alter the behavior of other cells. Inflammatory responses are an important defense the body uses against harmful stimuli such as infections or tissue damage.
Mr. Schutt believes that this study, published in the journal Nature Immunology, provides additional, verifiable evidence that unstable proteins can cause dysfunctional cells. The result of Dr. Udalova’s study augments Mr. Schutt’s own careful research combining free amino acids with the nucleic acids to cause formerly unstable proteins to realign. This study provides further convincing evidence of the efficacy of both of Mr. Schutt’s formulae, Triamino™ and TAFA400™.
More than thirty seven years in development, the Triamino™ Formula is a unique and revolutionary Amino Ion releasing hydrogen-bonded molecule. Triamino™ has been tested for verification by means of a series of sophisticated trials utilizing NMR (Nuclear Magnetic Resonance). In addition, an internationally recognized bio- research laboratory has conducted a series of LD 50 studies consisting of inoculations by subcutaneous infusion, intravenous injection, inhalation and oral feeding. All test results indicate this new molecule is essentially non-toxic with no side effects, and is considered as safe as distilled water. This new molecule is a water-soluble blend of amino acids that embodies nature- based healing agents delivered through oral, inhalant, topical, and both inter-and intra- (arterial or venous) administration. The structure of this new Triamino™ molecule is based on a proprietary formula that facilitates healing across a broad spectrum of medical ailments and health conditions. It does so because the Free Amino Ions in Hydrous solution inundate and bond to the nucleic acids within the unstable proteins of dysfunctional cells. The resultant biosynthesis causes the unstable proteins to align and become stable, returning the cells to their normal functioning as programmed by their original DNA coding which is still implanted within their DNA structure. This mechanism also causes reactivation of the Proliferative phase regulated by the DNA, thus significantly accelerating the healing process. The Triamino™ molecule is derived from natural, based amino-acids which ensure an FDA GRAS (Generally Recognized As Safe) status. The molecule is not a pharmaceutical drug. It has multiple applications in the treatment of both human and animal health issues.
Triamino Fulvate (TAFA400™) is the second and newest Molecule developed by Mr. Schutt and is available in a unique formula that combines the Triamino™ Molecule & Fulvic Acid (Carbohydrate Derived Fulvic Acid) that eliminates the problems encountered with mineral derived Fulvic Acid. CHD Fulvic Acid in a chemically pure pharmaceutical grade has not only augmented the Triamino™ molecule, but has added to the
benefits of Triamino™ to produce the most effective non-toxic, all-natural broad spectrum anti- fungal, anti-bacterial, anti-microbial, anti-viral agent known to mankind. This new formulation gives it the propensity to more easily bond to the nucleic acids within the cellular protein and causes the nucleus to function as originally programmed by its DNA. The addition of Fulvic Acid to the Triamino™ Molecule aids in the bonding process because fulvates strongly bond to all proteins.
Toxic microbes, viruses and fungi do not and cannot form immunity to the action of the fulvate component of this motity due to its superb ability to bond to the protein portion of the covering membrane of microbial cells, viral forms and fungi. Triamino Fulvate (TAFA400™) can be regarded as a non-specific entry inhibitor to viral coat proteins. It exhibits broad spectrum anti-viral activity against most envelope viruses such as Vaccinia, Herpes, HIV, Hepatitis C, and Influenza, including H5Nl. This new molecule notably maintains all the benefits of Triamino™ and adds the superb anti-microbial, anti-viral and anti-fungal effects of CHD Fulvic Acid without any toxic side effects. It also accelerates the speed of Triamino™’s anti-inflammatory action.